broad oncology portfolio focused on expanding access to more affordable treatments for multiple types of cancer.”
Dr Arun Chandavarkar, CEO and Joint Managing Director, Biocon, said:“ We are extremely pleased with the regulatory progress of our biosimilars in the U. S. The FDA’ s acceptance for review of our second BLA for a proposed biosimilar developed by Biocon and Mylan is an outcome of our strong R & D and manufacturing capabilities. Once approved, our proposed biosimilar pegfilgrastim
will provide a high quality alternative to branded pegfilgrastim( Neulasta ®) for cancer patients during cytotoxic chemotherapy. It will expand our oncology portfolio and further enable us to fulfil our promise of making cancer-care affordable and accessible for patients across the globe.”
Govt extends Rotavirus vaccine immunization under UIP
“ It is our endeavour to protect each and every child in the country from vaccine preventable diseases. This is a new milestone towards expanding the coverage of full immunization in the country aimed at reducing child mortality”, Mr J P Nadda, Union Minister for Health and Family Welfare stated this as he announced the expansion of the Rotavirus vaccine under its Universal Immunization Programme( UIP) in five additional states in function at Agartala.
“ This life-saving vaccine will not only improve the health of our children but will also reduce hospitalization and other conditions associated with diarrhoea due to Rotavirus such as malnutrition, delayed physical and mental development among children. Reduced hospitalization reduces the economic burden on the family and the health cost burden on the country”, Mr Nadda said. He further stated that the Rotavirus vaccine
has been developed indigenously, under a public-private partnership by the Ministry of Science and Ministry of Health and Family Welfare. This, therefore, is a landmark achievement under‘ Make in India’ initiative, he stated.
The vaccine will prevent Rotavirus diarrhoea in children which accounts for approximately 40 per cent of hospitalizations from diarrhoea in India. Rotavirus diarrhoea is responsible for nearly 78,000 deaths, 32 lakh out-patient visits and nearly 9 lakh hospitalizations every year. Rotavirus diarrhoea can also lead to dehydration, malnutrition and delayed physical and mental development in children.
BIOVOICENEWS. COM 59